AzTrials
AzTrials

NeuropathySENSATIONNCT05483816

MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts

A study testing VR+TENS in people with Neuropathy and Neuropathy, Painful, run by ETH Zurich at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
What is being tested?
VR+TENS
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteSwitzerland
Study dates
30 Jun 2022to 28 Feb 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 18-80
  • Visual acuity\>6 on Snellen visual acuity chart
  • Age 18-80
  • Visual acuity\>6 on Snellen visual acuity chart
  • Diagnosis of peripheral neuropathy
  • Pain in lower limbs\>=3 cm on VAS scale

Who cannot join

  • Pregnancy
  • Cognitive deficits (Mini Mental State Examination\<23)
  • Cyber-sickness
  • Prior or current psychological diseases
  • Pacemakers
  • Epilepsy
Show all 26Show fewer
  • Claustrophobia
  • Other MRI contraindications
  • Unhealed fractures
  • Unhealed wounds
  • Cancerous growth in proximity to feet
  • Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins
  • for patients:
  • Pregnancy
  • Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)
  • Ulcers
  • Cognitive deficits (Mini Mental State Examination\<23)
  • Cyber-sickness
  • Prior or current psychological diseases
  • Pacemakers
  • Epilepsy
  • Claustrophobia
  • Other MRI contraindications
  • Unhealed fractures
  • Unhealed wounds
  • Cancerous growth in proximity to feet

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Stanisa Raspopovic, Prof. Dr. contact

44 632 58 39 ext. +41

stanisa.raspopovic@hest.ethz.ch

Switzerland1 site, 1 recruiting
  • ETH Zurich

    Zurich, Canton of Zurich, 8006

    Stanisa Raspopovic, Prof. Dr., 44 632 58 39 ext. +41, stanisa.raspopovic@hest.ethz.ch

    Recruiting

Other trials in Switzerland

About this study

Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.

Today, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.

The aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.

Read the detailed description

One of the notoriously hardest and long-established challenges for the whole scientific community concerns the complete understanding and, consequently, the treatment of neuropathy. This condition results in an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Falling is one of the major health-related problems. In the United Kingdom, more than one fourth of accidents requiring hospital treatment are a consequence of falls. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle (which promotes other long-term complications, e.g. of the cardiovascular system). This has also very severe impacts on the patients' psychological health. Indeed, the comorbidity of neuropathy with anxiety and depression has been estimated to be 59% in the U.S population. Patients may develop neuropathic pain, associable to the aberrant sensory inputs. Experiencing pain impacts even more on gait stability and on the fear of falling. Given the complexity of the underlying mechanisms, chronic neuropathic pain is one of the most prevalent, costly and disabling health issue, hitting a huge portion of the world population. Chronic pain, indeed is estimated to affect approximately 19% of the adult European population. Nowadays, current chronic pain therapies (either behavioural, pharmacological or surgical) are inefficient, as demonstrated by the high prevalence, low rates of functional recovery and the assiduous reliance on opioid analgesics.

The reasons of such lack of efficacy can be attributed to different factors, among which the lack of therapies addressing the multidimensions of pain, as pain is not a unitary phenomenon, rather a multidimensional outcome of sensory-discriminative and motivational-affective components, that should be synergistically accounted for, and the lack of reliable biomarkers: objective indicators of pain are needed to demonstrate therapeutic target engagement, to stratify patients and to predict disease progression or therapeutic responses.

These factors are the main focuses of this study, whose aim is to develop a multisensory platform for pain, detecting pain through physiological recordings and delivering a therapy when such physiological biomarkers are detected. First the detection of pain is exploited through electrophysiology and then the therapy is delivered by means of Virtual Reality (VR) and Transcutaneous Electrical Nerve Stimulation (TENS), in order to target both physiological and affective/cognitive components of neuropathic pain. VR and TENS have already singularly produced encouraging results in literature[26-29]. However, these results are conflicting and not conclusive. The investigators believe that the combination of these technologies, which targets all the different aspects of pain, will really provide a successful and lasting benefit to the patients chronic pain.

Furthermore, the nature of the platform, which includes the use of non-invasive electrical stimulation, allows to recreate sensations in parts of the body where the subjects don't feel sensations anymore. Indeed, thanks to years of research, the Neuro-engineering laboratory found optimal stimulation parameters and electrode placement which are able to elicit sensations far from the electrodes placement. Electrodes are indeed placed on healthy parts of the nerves, but the perceived sensation is in the extremities. This allows to target also another extremely common consequence of neuropathy: sensory loss. This symptom forces patients to have an altered gait strategy, impaired balance and a five-fold increased risk of falling. Therefore, in this study the investigators will monitor also the potential benefits of the platform on these aspects.

As for the imaging sessions, before starting the imaging sessions, patients will be assessed to obtain potential information that might impact on the results.

Healthy participants and patients will be asked to participate in two-three fMRI sessions. Prior to the scanning, a calibration procedure will take place, to understand the subject's stimulation parameters and characterize the location and type of sensations elicited.

During the fMRI sessions, the investigators will examine the neural correlates of the referred perceptions and any pain relief induced using the non-invasive TENS stimulation approach. During these sessions different types of stimulations will be performed (with the TENS stimulation system, with vibrotactile stimulators, and with visual stimulations). Resting state fMRI will be used to examine functional connectivity between different regions of interest. Each fMRI session will last ~70-80 minutes.

Being tested
VR+TENS
Medical subject headings
Neuropathy, Painful, Diabetic Neuropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VR+TENSCombination product

    The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality

Study groups in NCT05483816
Study groupRoleWhat they receive
Virtual Reality and Transcutaneous Electrical Nerve StimulationExperimentalfor healthy subjects: painful stimulus induction (electrical stimulation) for patients: focus/non focus on pain Therapy is released in presence of pain
Receives: Combination Product: VR+TENS
Virtual Reality onlyActive comparatoronly VR delivers therapy
Receives: Combination Product: VR+TENS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in pain level

    Change in pain level reported by the subjects, 10 cm Visual Analogue Scale (VAS) scale with anchor points 0 = No pain and 10 = Worst imaginable pain, Numerical Pain Rating Scale (NPRS), and the Neuropathic Pain Symptom Inventory (NPSI)

    Measured: Through study completion, up to 10 days

  2. Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) before and after the treatment

    will be measured through functional Magnetic Resonance Imaging (fMRI) sessions

    Measured: baseline and 1 week follow-up

  3. Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet

    The brain activity will be measured while stimulating the subjects in three different locations: 1.somatotopic 2. in-loco 3. at the ankle

    Measured: baseline, pre-intervention

Secondary outcomes (9)
  1. Changes in EEG

    EEG: electroencephalography is a non-invasive measure. A cap is placed on the subject's head and detects the brain activity. In order to do so, a conduction gel (washable with water) is placed on each electrode. We will measure: general Power Spectral Density, frequency bands power (delta, theta, alpha, beta, gamma), connectivity, phase locking value, entropy.

    Measured: Through study completion, up to 10 days

  2. Changes in Skin Conductance signatures

    Skin Conductance (SC): skin conductance is a measure of the electrodermal activity. It is measured through a couple of non invasive electrodes on the palm of the patient. We will extract features such as peak amplitude, latency, variation, derivative.

    Measured: Through study completion, up to 10 days

  3. Percentage of session completed

    Compliance = % of each session completed.

    Measured: post-intervention

  4. Changes in Anxiety and Depression

    measured through validated questionnaires: Beck Anxiety Inventory and Beck Depression inventory

    Measured: baseline, post-intervention

  5. Changes in Quality of life

    measured through validated questionnaires Neuro-Quality of life

    Measured: baseline, post-intervention

  6. changes in balance

    Balance will be measured by validated tests (Berg Balance Scale), that range between 0 and 56 (lower values=higher impairment)

    Measured: baseline, during the intervention, post-intervention

  7. changes in the speed to perform the Timed Up and Go (TUG) test

    Functional mobility will be measured by the Timed Up and Go (TUG) test which measures the time that it takes a person to rise from a chair, walk 7 m, turn around and return and sit in the chair.

    Measured: baseline, during the intervention, post-intervention

  8. changes in the ankle dorsiflexion angle is derived from gait analysis

    The ankle dorsiflexion angle is derived from gait analysis. The angle of the ankle at the time the foot contacts the floor during a step is derived. This is repeated for at least 5 different walks, and the average of those 5 walks is calculated for further analysis.

    Measured: baseline, during the intervention, post-intervention

  9. changes in speed and cadence in the 10 meter and 6 min walk test

    In the 10 meter walk test, the time taken by the participant to walk 10 meters is recorded. The test is repeated and the average is taken for analysis.

    In the 6 min walk test, the steps taken by the participant in 6 min walking are recorded.

    Measured: baseline, during the intervention, post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2022
  2. Study start30 Jun 2022
  3. Primary completion28 Feb 2026 (estimated)
  4. Study completion28 Feb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05483816
Sponsor's protocol ID
NeuroengLab
Acronym
SENSATION
Status last verified
Nov 2024
First submitted
14 Jul 2022
Last updated
18 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing VR+TENS in people with Neuropathy and Neuropathy, Painful, run by ETH Zurich at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stanisa Raspopovic, Prof. Dr. (44 632 58 39 ext. +41, stanisa.raspopovic@hest.ethz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in pain level (time frame: Through study completion, up to 10 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in